The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application ...

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) Injection 8mg, submitted by US biotech ...

A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial. Novartis ...

Scientists discovered two genes involved in hyperemesis gravidarum, a condition that can cause extreme nausea and vomiting ...

While most students spend their January break catching up on well-deserved sleep or binge-watching Netflix, 20-year-old Ruby ...

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

Launch Fayette student entrepreneur Aadi Vaidya, a Junior at McIntosh High School, won ‘First Honors” and the ‘Best In ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...